Industry News (Herpes Therapies)

Genital Herpes Considered as Omniferon Disease Target

Published in Medical Letter on the CDC and FDA, November 3rd, 1997

Viragen, Inc., Plantation, Florida, and its subsidiary, Viragen (Europe) Ltd. announced that they are placing genital herpes on fast-track consideration as a primary disease target in their global clinical development strategy for Omniferon, the company's second generation natural alpha interferon.

The company said it is intensifying its consideration of genital herpes as a result of a new study released by the U.S. Centers for Disease Control and Prevention (CDC) and published in the New England Journal of Medicine, which suggests that 45 million Americans alone are infected with genital herpes, although only 9 percent of the study participants knew they had the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA

Source: Medical Letter on the CDC and FDA (1997-11-03)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry